Lexaria Bioscience Corp. LEXX
4.64 USD -0.04 (-0.85%)
At closeNov 11, 2026, 4:00 PM EST
4.74 +0.10 +2.16%
After hours · Nov 11, 4:00 PM ET
4.46 Day range 4.78
2.43 52-week range 21.60
- YTD
- -49.89%
- 1 year
- -72.38%
News
benzinga.com Lexaria Bioscience Strikes Agreement With Undisclosed Pharma Firm To Investigate Lexaria's DehydraTECH Technology With One, More PharmCo Modules Lexaria Bioscience Corp. (NASDAQ:LEXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces that it has entered into an Agreement with an unnamed pharmaceutical…
benzinga.com Lexaria Bioscience Completes Enrollment And Continues Dosing On Schedule In Two Oral Semaglutide Pilot Study Comparing DehydraTECH Formulations To Wegovy Tablets Lexaria Bioscience Corp. (NASDAQ:LEXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, reports that full enrollment has been reached and dosing continues on schedule with
benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session Gainers Silexion Therapeutics (NASDAQ:SLXN) shares moved upwards by 11.0% to $0.17 during Friday's after-market session. The company's market cap stands at $2.4 million. Lexaria Bioscience…
benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session Gainers Alaunos Therapeutics (NASDAQ:TCRT) stock rose 34.9% to $2.94 during Thursday's after-market session. The market value of their outstanding shares is at $7.6 million. Senti Biosciences…- benzinga.com Lexaria Bioscience Announces Results From Animal Study GLP-1-A26-1 Evaluating Both DehydraTECH-CBD Compositions And DehydraTECH-Semaglutide; Unfortunately, The DHT-SEMA Concentrations In Brain Tissue Were All At Levels Below The Lower Limit Of Quantitation Of The Bioassay Utilized In This Study Lexaria Bioscience Corp. (NASDAQ:LEXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is pleased to provide the following results from animal study GLP-1-A26-1 (the